Inhibition of NF-κB activation by LUBAC inhibitors sensitised lung squamous cell carcinoma to cisplatin, suggesting a possible utilisation of these inhibitors and other NF-κB pathway inhibitors (e.g. curcumin) also in HNSCC patients89–92. Here, NFKB1 is linked to head and neck squamous cell carcinoma.